Jaguar health launches canalevia-ca1 (crofelemer) for the treatment of chemotherapy-induced diarrhea (cid) in dogs

The canalevia.com website, a resource for veterinarians and dog owners, is now live canalevia™-ca1 is the first and only treatment for chemotherapy-induced diarrhea (cid) in dogs to receive any type of approval from fda san francisco, ca / accesswire / january 4, 2022 / jaguar health, inc. (nasdaq:jagx) today announced the launch of canalevia™-ca1 (crofelemer delayed-release tablets), jaguar's plant-based prescription drug for the treatment of chemotherapy-induced diarrhea (cid) in dogs. canalevia-ca1 received conditional approval from the fda on december 21, 2021.
JAGX Ratings Summary
JAGX Quant Ranking